[{"orgOrder":0,"company":"Acella Pharmaceuticals","sponsor":"Milla Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Acella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Syrup","sponsorNew":"Acella Pharmaceuticals \/ Milla Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acella Pharmaceuticals \/ Milla Pharmaceuticals"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Syrup","sponsorNew":"Milla Pharmaceuticals \/ Alter Pharma group","highestDevelopmentStatusID":"15","companyTruncated":"Milla Pharmaceuticals \/ Alter Pharma group"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"NMD PHARMA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Immunology","graph2":"Phase III","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Leiden University Medical Center \/ NMD PHARMA","highestDevelopmentStatusID":"10","companyTruncated":"Leiden University Medical Center \/ NMD PHARMA"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Pyridostigmine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Pyridostigmine Bromide, is a cholinesterase inhibitor small molecule drug administered orally for soman nerve agent poisoning in adults.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 21, 2024

                          Lead Product(s) : Pyridostigmine

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Pyridostigmine Bromide, generic version of Mestinon, is a cholinesterase inhibitor small molecule drug administered orally as a syrup for myasthenia gravis.

                          Product Name : Mestinon-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 12, 2023

                          Lead Product(s) : Pyridostigmine

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Milla Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Leiden University Medical Center

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Leiden University Medical Center

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 26, 2023

                          Lead Product(s) : Pyridostigmine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : NMD PHARMA

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Abbreviated New Drug Application (ANDA) for a generic version of Mestinon (Pyridostigmine Bromide Syrup) 60 mg/5mL, is indicated for symptomatic treatment of myasthenia gravis.

                          Product Name : Pyridostigmine Bromide-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 19, 2022

                          Lead Product(s) : Pyridostigmine

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Alter Pharma group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          University of Aarhus

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          University of Aarhus

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Lead Product(s) : Pyridostigmine

                          Therapeutic Area : Neurology

                          Study Phase : Undisclosed

                          Sponsor : Novo Nordisk | Svend Faelding Humanitarian Foundation | Copenhagen University Foundation for Medical Students | Hoejmosegaard Foundation | Holger Rabitz og Hustru Doris Mary foedt Phillipps Mindelegat | Lundbeck Foundation | Wilhelm Frank og Angelina Fran

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 09, 2015

                          Lead Product(s) : Pyridostigmine

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Novo Nordisk | Svend Faelding Humanitarian Foundation | Copenhagen University Foundation for Medical Students | Hoejmosegaard Foundation | Holger Rabitz og Hustru Doris Mary foedt Phillipps Mindelegat | Lundbeck Foundation | Wilhelm Frank og Angelina Fran

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Lead Product(s) : Pyridostigmine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Phase II

                          Sponsor : Nathan Kline Institute for Psychiatric Research | Oklahoma State University | National Heart, Lung, and Blood Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 12, 2011

                          Lead Product(s) : Pyridostigmine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Nathan Kline Institute for Psychiatric Research | Oklahoma State University | National Heart, Lung, and Blood Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank